Summary
The tissue expression of c-erbB-2 protein in breast cancer is a marker of poor prognosis in a number of studies. More recently it has also been suggested that c-erbB-2 expression may predict response to systemic therapy in patients with advanced breast cancer. The measurement of c-erbB-2 protein in the serum of breast cancer patients has now been reported, but the significance of this finding is not clear. In this study an ELISA assay was used to measure c-erbB-2 in the sera of 23 normal controls, 46 benign breast disease patients, and 119 breast cancer patients. Elevated serum c-erbB-2 protein levels were detected in 13% (3/23) of normal controls, 15% (7/46) of benign disease patients, 15% (7/46) of Stage I/II patients, 26% (9/35) of Stage III patients, and 21% (8/38) of Stage IV patients. The tissue expression of the c-erbB-2 protein showed no association with detection of the serum c-erbB-2 protein (p = 0.31). In the 67 Stage III and IV patients who had assessable disease the presence of the c-erbB-2 protein in the serum bore no relationship to response to hormonal therapy (p = 0.71). Serum detection of the c-erbB-2 protein in Stage I/II patients predicted for a worsening of both survival outcome (p = 0.002) and disease free interval (p = 0.002). A worse outcome was also seen for the Stage III patients (p = 0.04) and Stage IV patients, although the latter did not reach statistical significance (p = 0.27).
This study found that the presence of c-erbB-2 in the serum of breast cancer patients was of prognostic significance for all stages of disease.
References
Singleton TP, Strickler JG: Clinical and pathological significance of the c-erbB-2 (HER-2/neu) oncogene. Path Annual 1: 165–190, 1992
Narita T, Funahashi H, Satoh Y, Takagi H: c-erbB-2 protein in the sera of breast cancer patients. Breast Cancer Res Treat 24: 97–102, 1992
Kandl H, Seymour L, Bezwoda WR: Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. Br J Cancer 70: 739–742, 1994
Kynast B, Binder L, Marx D, Zoll B, Schmoll HJ, Oellerich M, Schauer A: Determination of a fragment of the c-erbB-2 translational product p185 in the serum of breast cancer patients. J Cancer Res Clin Oncol 119: 249–253, 1993
Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Rubens R: Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union against Cancer, Geneva, Switzerland. Cancer 39: 1289–1294, 1977
Bender MedSystems:s p185 HER-2 Product Information Manual. Vienna, Austria
Nicholson RI, Colin P, Francis AB et al.: Evaluation of an enzyme immunoassay for oestrogen receptors in human breast cancers. Cancer Res (Suppl) 46: 4299s-4304s, 1986
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235: 177–182, 1987
Lovekin C, Ellis IO, Locker A, Robertson JFR, Bell J, Nicholson RI, Gullick WJ, Elston CW, Blamey RW: c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 63: 439–443, 1991
Anderson TI, Paus E, Nesland JM, McKenzie SJ, Borresen AL: Detection of c-erbB-2 related protein in sera from breast cancer patients — Relation to ERB2 gene amplification and c-erbB-2 protein overexpression in tumour. Acta Oncol 34: 499–504, 1995
Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK: Estrogen dependent tamoxifen resistant tumorigenic growth of MCF-7 cells transfected with HER-2/neu. Br Cancer Res Treat 24: 85–95, 1992
Nicholson RI, McClelland RA, Findlay P, Eaton CL, Gullick WJ, Dixon AR, Robertson JFR, Ellis IO, Blamey RW: Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 29A: 1018–1023, 1993
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Willsher, P.C., Beaver, J., Pinder, S. et al. Prognostic significance of serum c-erbB-2 protein in breast cancer patients. Breast Cancer Res Tr 40, 251–255 (1996). https://doi.org/10.1007/BF01806813
Issue Date:
DOI: https://doi.org/10.1007/BF01806813